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Introduction 
 
 
1. INTRODUCTION1, 2, 3, 4 
 Cancer can be defined as a disease in which a group of abnormal cells grow 
uncontrollably by disregarding the normal rules of cell division. Cancers arise 
approximately in one among every three individuals. DNA mutations arise normally at a 
frequency of 1 in every 20 million per gene per cell division. The average number of cells 
formed in any individual during an average lifetime is 10
16
 (10 million cells being replaced 
every second!). Risk of cancers are increased by infectious agents including viruses 
[Hepatitis B virus (HBV1), Human Papillomavirus (HPV), Human Immunodeficiency 
Virus(HIV)-increase risk of Nasopharyngeal, Cervical carcinomas and Kaposi’s Sarcoma] 
and bacteria such as Helicobacter pylori (Stomach cancers). 
 Initiation and progression of cancer is also due to exposure to cancer-causing agents 
(carcinogens, mutagens). These are present in the food and water, in the air, and in 
chemicals and sunlight that people are exposed to. Since epithelial cells cover the skin, line 
the respiratory and alimentary tracts, and metabolize ingested carcinogens, it is not 
surprising that over 90% of cancers originate from epithelia (carcinomas). In less than 10% 
of cases, a genetic predisposition increases the risk of cancer developing a lot earlier. (e.g. 
Certain childhood leukemia’s, retinal cancers etc.) 
 Although cancer can occur in persons of every age, it is common among the aging 
population. 60% of new cancer cases and two thirds of cancer deaths occur in persons >65 
years. The incidence of common cancers (e. g. breast, colorectal, prostate, lung) increases 
with age. The exponential rise in many cancers with age fits with an increased susceptibility 
to the late stages of carcinogenesis by environmental exposures. Lifetime exposure to 
estrogen may lead to breast or uterine cancer; exposure to testosterone leads to prostate 
cancer. The decline in cellular immunity may also lead to certain types of cancer that are 
highly immunogenic (e.g. lymphomas, melanomas). Accumulation of DNA mutations have 
to be amplified to constitute a cancer, therefore the longer the life span, the higher the risk of 
developing cancer. 
The six hallmarks of cancers are: 
 Immortality: continuous cell division and limitless replication 
 Produce ‘Go’ signals (growth factors from oncogenes) 
 Override ‘Stop’ signals (anti-growth signals from tumour suppressor genes) 
 Resistance to cell death (apoptosis) 
 Angiogenesis: Induction of new blood vessel growth 
 Metastasis: Spread to other sites 
                                             CANCER CELL                                     NORMAL CELL 
 
 Fig.1 Hallmarks of cancer 
Almost all cancers share some or all of the above mentioned six traits depending on 
the tumour. 
The available anticancer drugs have distinct mechanisms of action which may vary 
in their effects on different types of normal and cancer cells. A single "cure" for cancer has 
proved elusive since there is not a single type of cancer but as many as 100 different types of 
cancer. In addition, there are very few demonstrable biochemical differences between 
cancerous cells and normal cells. For this reason the effectiveness of many anticancer drugs 
is limited by their toxicity to normal rapidly growing cells in the intestinal and bone marrow 
areas. A final problem is that cancerous cells which are initially suppressed by a specific 
drug may develop a resistance to that drug. For this reason cancer chemotherapy may consist 
of using several drugs in combination for varying lengths of time. 
The majority of drugs used for the treatment of cancer today are cytotoxic (cell-
killing) drugs that work by interfering in some way with the operation of the cell's DNA. 
Cytotoxic drugs have the potential to be very harmful to the body unless they are very 
specific to cancer cells - something difficult to achieve because the modifications that 
change a healthy cell into a cancerous one are very subtle. A major challenge is to design 
new drugs that will be more selective for cancer cells, and thus have lesser side effects. The 
reason for this is simple: cancer cells are not foreign to the body but are simply subtly 
mutated forms of normal human cells, and it is very different to synthesize drugs that can 
tell the difference. 
 
 
 
 
 
Types of cancer: 
 Cancers may be categorized based on the functions/locations of the cells from which 
they originate. The following terms are commonly used to categorize by their tissue (cell 
type) of origin. 
 Carcinoma- a tumor derived from epithelial cells, those cells that line the 
surface of our skin and organs. This is the most common cancer type and 
represents about 80-90% of all cancer cases reported. 
 Sarcoma- a tumor derived from muscle, bone, cartilage or connective tissues. 
 Leukemia- a cancer derived from white blood cells or their precursors. The 
cells that form both white and red blood cells are located in the bone marrow. 
 Lymphoma- a cancer of bone marrow derived cells that affect the lymphatic 
system. 
 Myelomas- a cancer involving the white blood cells responsible for the 
production of antibodies (B lymphocytes or B-cells) 
Each type of cancer is unique with its own causes, symptoms, and method of 
treatment. The most common cancers are: 
 Breast cancer 
 Colorectal cancer 
 Lung cancer 
 Prostate cancer 
 Skin cancer 
 Bladder cancer 
 Renal cell carcinoma 
 Pancreatic cancer 
 Leukemia 
Globally, cancer of the colon and rectum
5, 6, 7
 is the third leading cause of cancer in 
males and fourth leading cause of cancer in females. The frequency of colorectal cancer 
varies around the world. It is common in the western world and is rare in Asia and Africa. In 
countries where the people have adopted western diets, the incidence of colorectal cancer is 
increasing. Factors that increase a person’s risk of colorectal cancer include high fat intake, 
a family history of colorectal cancer and polyps, the presence of polyps in the large intestine, 
and chronic ulcerative colitis. 
The various receptor targets for cancer are as follows: 
 Mammalian target of rapamycin  receptor (mTOR) 
 Epidermal growth factor receptor (EGFR) 
 Platelet-derived growth factor receptor (PDGF) 
 Adenosine receptor 
 Estrogen receptor 
 G-protein-coupled receptors 
 Chemokine receptors 
 Toll-like receptors 
 Cyclin-dependent kinase  receptors (CDK) 
 Cannabinoid receptors 
 Fibroblast growth factor receptors (FGF) 
 Insulin-like growth factor receptors (IGF) 
 Hepatocyte growth factor receptors (HGF) 
 Interferon receptors (IFN) 
The mammalian target of rapamycin (mTOR) 
8, 9, 10, 11
 is an intacellular kinase that 
controls the production of several proteins through its phosphorylation of translational 
machinery. mTOR-activated proteins promote several hallmarks of cancer such as cell 
growth and proliferation, angiogenesis, and bioenergetics. Since mTOR acts as a neoplastic 
switch that is frequently turned on by many mutations found in cancer, inhibition of mTOR 
may offer a promising new strategy for cancer therapy. 
 
Fig.2 mTOR signaling pathway 
The mammalian target of rapamycin (mTOR), also known as FKBP 2-rapamycin 
associated protein (FRAP), a phosphatidylinositol 3-kinase (PI3K) related serine/threonine 
kinase.  The pathway in which it plays a prominent part regulates the growth, proliferation, 
motility and survival of cells and also angiogenesis.  This central regulation of cell growth 
and proliferation is activated by growth factor/mitogenic stimulation activation of the 
phosphatidylinositol 3-kinase (PI3K)/AKt signaling pathway
12,13,14
, one of the most 
frequently dysregulated pathways in cancer.  This pathway has been shown to cooperate in 
prostate cancer progression and the transition to androgen-independent disease.  Rapamycin, 
a known mTOR inhibitor is a bacterial product that was originally of interest for its 
antifungal properties.  It was subsequently found to have immunosupressive and 
antiproliferative properties.  While it was being tested as an immunosuppressive agent to 
prevent organ rejection in transplant patients, the drug rapamycin was also discovered to 
have anti tumor properties.  Rapamycin shows promise against few types of cancers 
particularly mantle cell lymphoma, endometrial cancer, and renal cell carcinoma.  The 
known mTOR inhibitor rapamycin and its analogues (RAD001, CCI-779, and AP23573) 
bind to the FKBP12/rapamycin complex binding domain (FRB) and suppress the signaling 
to the downstream targets p70S6K and 4E-BP1.  The potent but non-specific inhibitors of 
PI3K, LY294002 and wortmannin, have also been shown to inhibit the kinase function of 
mTOR but it inhibits by targeting the catalytic domain of protein.  Recently it has been 
shown that mTOR exists in two complexes.  mTORC1, a rapamycin sensitive complex 
signaling to p70S6K and 4E-BP1 and mTORC2, a rapamycin insensitive complex that 
signals to AKt.  Inhibition of mTORC1 alone can block a desirable negative feedback 
mechanism, thereby causing an increase of PI3K/AKt signaling and reducing the 
effectiveness of the inhibitors.  This negative feedback mechanism can be restored by 
inhibiting mTORC2.  Therefore it is proposed that direct targeting of the kinase domain of 
mTOR would inhibit the signaling through both mTORC1 and mTORC2 and that such a 
compound would exhibit a different pharmacology compared with rapamycin. Since there is 
no available crystal structure of mTOR, mTOR homology model was built based on the X-
ray crystal structure of the closely related protein PI3Kγ.   
1.1. Homology modeling:
 15
 
 The ultimate goal of protein modeling is to predict a structure from its sequence with 
an accuracy that is comparable to the best results achieved experimentally. Protein modeling 
is the only way to obtain structural information if experimental techniques fail. Many 
proteins are simply too large for NMR analysis and cannot be crystallized for X-ray 
diffraction. 
 Homology modeling is a multistep process that can be summarized in seven steps: 
1. Template recognition and initial alignment 
2. Alignment correction 
3. Backbone generation 
4. Loop modeling 
5. Side-chain modeling 
6. Model optimization 
7. Model validation 
                                    
Fig. 3 Homology modeling 
Every homology model contains errors. The number of errors (for a given method) 
mainly depends on two values: 
 The percentage sequence identity between template and target. If it is greater 
than 90%, the accuracy of the model can be compared to crystallographically determined 
structures, except for a few individual side chains. From 50% to 90% identity, the root mean 
square (rms) error in the modeled coordinates can be as large as 1.5 A°, with considerably 
larger local errors. If the sequence identity drops to 25%, the alignment turns out to be the 
main bottleneck for homology modeling, often leading to very large errors. 
 The number of errors in the template. 
 
1.2. Drug discovery:
 16, 17, 18
 
Medicinal chemistry blends synthetic chemistry, molecular modeling, computational 
biology, structural genomics and pharmacology to discover and design new drugs, and 
investigate their interaction at the molecular, cellular and whole-animal level.  
 It combines empirical knowledge from the structure-function relationships of known 
drugs with rational designs optimizing of known drugs with rational designs optimizing the 
physiochemical properties of drug molecules. 
 The process of drug discovery involves the identification of candidate molecules, 
synthesis, characterization, screening for therapeutic efficacy and toxicity studies. The 
process of finding a new drug against a chosen target for a particular disease usually 
involves high-throughput screening (HTS), wherein large libraries of chemicals are tested 
for their ability to modify the target. 
 Drug discovery and development can broadly follow two different paradigms- 
Physiology-based drug discovery and Target-based discovery. The main difference between 
these two paradigms lies in the time point at which the drug target is actually identified. 
 Physiology-based drug discovery follows physiological readouts, for example, the 
amelioration of a disease phenotype in an animal model or cell-based assay. A purely 
physiology-based approach would initially forgo target identification/validation and instead 
jump right into screening. Identification of drug target and the mechanism of action would 
follow in later stages of the process by deduction based on the specific pharmacological 
properties of lead compounds. 
 By contrast, the road of target-based drug discovery begins with identifying the 
function of a possible therapeutic target and its role in disease. 
 One way to find promising drug candidates is to investigate how the target protein 
interacts with randomly chosen compounds. This is done by using compound libraries which 
can contain more than a million synthetic and natural compounds. These libraries are then 
tested against the target protein. This is most often done in so called high-throughput 
screening facilities. The most promising compounds obtained from the screening process are 
called hits-these are the compounds showing binding activity. Some of these hits are then 
promoted to lead compounds-candidate structures which are further refined and modified in 
order to achieve more favourable interactions and less side-effect. 
 Advances in computing power and in structure determination by X-ray 
crystallography and NMR have made computer-aided drug design (CADD) and structure-
based drug design (SBDD) essential tools for drug discovery.  
 The main advantages of computational methods over wet-lab experiments are as 
follows: 
 Low costs, no compounds have to be purchased externally or synthesized by a 
chemist. 
 It is possible to investigate compounds that have not been synthesized yet. 
 Conducting high-throughput screening (HTS) experiments is expensive and 
virtual screening (VS) can be used to reduce the initial number of compounds 
before using high-Throughput Screening (HTS) methods. 
 Huge chemical search space. The number of possible virtual molecules available 
for VS is much higher than the number of compounds presently available for 
HTS. 
1.2.1. CADD of lead compounds: 
 A detailed knowledge of a target binding site significantly aids in the design of novel 
lead compounds intended to bind with that target. In cases, where enzymes or receptors can 
be crystallized, it is possible to determine the structure of the protein and its binding site by 
X-ray crystallography. Molecular modeling software can then be used to study the binding 
site, and to design molecules which will fit and bind to the site-de novo drug design. 
 In some cases, the enzymes or receptor cannot be crystallized and so X-ray 
crystallography cannot be carried out. However, if the structure of an analogous protein has 
been determined, this can be used as the basis for generating a computer model of the 
protein (Homology Modeling). Homology Modeling relies on the identification of one or 
more known protein structures likely to resemble the structure of the query sequence, and on 
the production of an alignment that maps residues in the query sequence to residues in the 
template sequence. The sequence alignment and template structure are then used to produce 
a structural model of the target. The quality of the model is dependent on the quality of the 
sequence alignment and template structure. 
 Lipinski’s rule of five19 is a rule of thumb to evaluate drug likeness or determine if a 
chemical compound with a certain pharmacological or biological activity has properties that 
would make it a likely orally active drug in humans. The rule is important for drug 
development where a pharmacologically active lead structure is optimized-step-wise for 
increased activity and selectivity, as well as drug-like properties as described by Lipinski’s 
rule. 
 
 a molecular weight less than 500 
 no more than 5 hydrogen bond donor groups 
 no more than 10 hydrogen bond acceptor groups 
 a calculated log P value less than +5 (log P is a measure of a drug’s 
hydrophobicity) 
1.2.2.  Molecular docking: 20, 21 
 Molecular docking programs try to predict how a drug candidate binds to a protein 
target without performing a laboratory experiment. Molecular docking software consists of 
two core components. 
 A search algorithm (sometimes called an optimization algorithm). The search 
algorithm is responsible for finding the best conformations of the ligand and 
protein system. A conformation is the position and orientation of the ligand 
relative to the protein. In flexible docking, a conformation also contains 
information about the internal flexible structure of the ligand and in some 
cases about the internal flexible structure of the protein. Since the number of 
possible conformations is extremely large, it is not possible to test all of 
them, therefore sophisticated search techniques have to be applied. Examples 
of some commonly used methods are Genetic Algorithms and Monte Carlo 
Simulations. 
 An evaluation function (sometimes called a score function). This is a function 
providing a measure of how strongly a given ligand will interact with a 
particular protein. Energy force fields are often used as evaluation functions. 
These force fields calculate the energy contribution from different terms such 
as the known electrostatic forces between the atoms in the ligand and in the 
protein forces arising from deformation of the ligand, pure electron-shell 
repulsion between atoms and effect from the solvent in which the interaction 
takes place. 
1.2.3. Pharmacophore mapping: 
 Pharmacophore mapping is a geometrical approach. A pharmacophore can be 
thought as a 3D model of characteristic features of the binding site of the investigated 
protein. It can also be thought of as a template, a partial description of a molecule where 
certain blanks need to be filled. Like QSAR models, pharmacophores can be built without 
knowing the structure of the target. This can be done by extracting features from compounds 
which are known experimentally to interact with the target in question. Afterwards, the 
derived pharmacophore model can be used to search compound databases (libraries) thus 
screening for potential drug candidates that may be of interest. 
 Identifying 3D pharmacophore is relatively easy for rigid cyclic structures. With 
more flexible structures, it is not so straightforward because the molecule can adopt a large 
number of shapes or conformations which place the important binding groups in different 
positions relative to each other. Normally only one of these conformations is recognized and 
bound by the binding site. This conformation is known as the active conformation. 
 In order to identify the 3D pharmacophore, it is necessary to know the active 
conformation. There are various ways in which this might be done. Rigid analogues of the 
flexible compound could be synthesized and tested to see whether activity is retained. 
Alternatively, it may be possible to crystallize the target with the compound bound to the 
binding site. X-ray crystallography could then be used to identify the structure of the 
complex as well as the active conformation of the bound ligand. 
1.2.4. Lead optimization: 
 Lead optimization is the complex, non-linear process of refining the chemical 
structure of a confirmed hit to improve its drug characteristics with the goal of producing a 
preclinical drug candidate. This stage frequently represents the bottleneck of a drug 
discovery program. 
 Once the important binding groups and pharmacophore of the lead compound have 
been identified it is possible to synthesize analogues that contain the same pharmacophore. 
Very few lead compounds are ideal. Most are likely to have low activity, poor selectivity, 
and significant side effects. They may also be difficult to synthesize, so there is an 
advantage in finding analogues with improved properties.  
 The following strategies are used to optimize the interactions of a drug with its target 
in order to gain higher activity and selectivity. 
 Variation of substituents 
 Extension of the structure 
 Chain extension/contraction 
 Ring expansion/contraction 
 Ring variations 
 Ring fusions 
 Isosteres and Bioisosteres 
 Simplification of the structure  
 Rigidification of the structure  
 Conformational blockers 
1.3. Quinoline: 
22
 
 Heterocycles form by far the largest of classical divisions of organic chemistry and 
are of immense importance biologically and industrially. The majority of pharmaceuticals 
and biologically active agrochemicals are heterocyclic. One striking structural features 
inherent to heterocycles, which continue to be exploited to great advantage by the drug 
industry lies in their ability to manifest substituents around a core scaffold in defined three 
dimensional representations. 
 For more than a century, heterocycles have constituted one of the largest areas of 
research in organic chemistry. Between them nitrogen and sulfur containing heterocyclic 
compounds have maintained the interest of researches through decades of historical 
development of organic synthesis.  
 Quinoline is a heterocyclic aromatic nitrogen compound characterized by a double 
ring structure that contains a benzene ring fused to pyridine at two adjacent carbon atoms. 
 Its principal use is as a precursor to 8-hydroxyquinoline, which is a versatile chelating agent 
and precursor to pesticides. Its 2- and 4-methyl derivatives are precursors to cyanine dyes. 
Oxidation of quinoline affords quinolinic acid (pyridine-2, 3-dicarboxylic acid), a precursor 
to the herbicide sold under the name "Assert". Like other nitrogen heterocylic compounds, 
such as pyridine derivatives, quinoline is often reported as an environmental contaminant 
associated with facilities processing oil shale or coal. Owing to high water solubility 
quinoline has significant potential for mobility in the environment, which may promote 
water contamination. Fortunately, quinoline is readily degradable by certain 
microorganisms, such as Rhodococcus species Strain Q1, which was isolated from soil and 
paper mill sludge.  
                                 
  
Quinoline was first extracted from coal tar in 1834 by Friedlieb Ferdinand 
Runge. Coal tar remains the principal source of commercial quinoline. It can be synthesized 
by various methods. 
E.g. Skraup Synthesis 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 
 
2. REVIEW OF LITERATURE 
2.1.  Cancer research is the intense scientific effort to understand disease processes and 
discover possible therapies. Though many diseases (such as heart failure) may have a worst 
prognosis than most cases of cancer, cancer is the subject of widespread fear. In this 
literature review few works are listed here in support of cancer research. 
B.Ganesh et.al, 
3 
(2009) A case-control study on diet and colorectal cancer from Mumbai, 
India. 
Rajaraman Swaminathan et.al, 
4
 (2009) reported the Cancer pattern and survival in a rural 
district in South India. 
Suzanne Hector et.al, 
7
 (2009) reported Apoptosis signaling proteins as prognostic 
biomarkers in colorectal cancer: A review 
J.Cardoso et.al, 
5
 (2007) reported the Expression and genomic profiling of colorectal cancer. 
H.E.Blum 
6
 (1995) Colorectal Cancer: Further population screening for early colorectal 
cancer. 
2.2. Being a key regulator in cell growth and proliferation, mTOR’s deregulation is 
associated with human diseases including cancer and diabetes. The following 
literatures are listed here in support of cancer. 
 
Carlos Garcia-Echeverria 
11 
(2010) Allosteric and ATP-competitive kinase inhibitors of 
mTOR for cancer treatment.  
Margit Rosner et.al, 
13
 (2008) The mTOR pathway and its role in human genetic diseases. 
JB Easton and PJ Houghton 
10
 (2006) mTOR and cancer therapy. 
Laura Asnaghi et.al., 
8
 (2004) mTOR: a protein kinase switching between life and death. 
Jie Chen, Yimin Fang 
15
 (2002) A novel pathway regulating the mammalian target of 
rapamycin (mTOR) signaling. 
2.3. Review related to modeling of target protein for drug design: 
Karunakar tanneeru et.al, 
24
 (2011) Ligand-based 3-D pharmacophore generation and 
molecular docking of mTOR kinase inhibitors. 
 
2.4. The synthetic versatility of quinoline allows us to generate more diverse analogues. 
Of the several work of quinoline, few of them are listed here in support of their 
different synthesis. 
K.D. Thomas et.al, 
38
 (2011) Design, synthesis and docking studies of new quinoline-3-
carbohydrazide derivatives as antitubercular agents. 
 
Afshin Zarghi et.al, 
37
 (2010) reported the Design, synthesis, and biological evaluation of 
ketoprofen analogs as potent cyclooxygenase-2 inhibitors. 
 
 
Mostafa M. Ghorab et.al, 
35
 (2009) Design, synthesis and anticancer evaluation of novel 
tetrahydroquinoline derivatives containing sulfonamide moiety. 
 
                   
Yue-Ling Zhao et.al, 
36
 (2005) reported the Synthesis and cytotoxic evaluation of certain 
4-anilino-2-phenylquinoline derivatives. 
 
2.5. Of the several works of quinoline, few of them are listed here in support of their 
wide variety of biological activity. 
 
Rajesh Kakadiya et.al, 
47
 (2010) Potent DNA-directed alkylating agents: Synthesis and 
biological activity of phenyl N-mustard–quinoline conjugates having a urea or 
hydrazinecarboxamide linker.    
                             
Afshin Zarghi et.al, 
48
 (2009) reported the Synthesis and biological evaluation of new 4-
carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. 
                                                      
 
Andrew N. Boa et.al, 
49
 (2005) reported the Synthesis of brequinar analogue inhibitors of 
malaria parasite dihydroorotate dehydrogenase. 
                            
 
Ya-Yun Lai et.al, 
50
 (2005) reported the Synthesis and biological relationships of 3’,6-
substituted 2-phenyl-4-quinolone-3-carboxylic acid derivatives as antimitotic agents. 
                              
          
 
 
 
 
2.6. Reviews realted to cytotoxic studies using MTT assay: 
 
Ichiro Miki et.al, 
46
 (1993) Simple colorimetric cell-cell adhesion assay using MTT stained 
leukemia cells.                      
Arjan A.van de Loosdrecht et.al, 
45
 (1991) Cell mediated cytotoxicity against U 937 cells by 
human monocytes and macrophages in a modified colorimetric MTT assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim and Objective 
 
3. AIM AND OBJECTIVE 
 Quinoline compounds are widely used as “parental” compounds to synthesize 
molecules with medical benefits, especially with anti-malarial and anti-microbial activities. 
Certain quinoline-based compounds also show effective anticancer activity. This broad 
spectrum of biological and biochemical activities has been further facilitated by the 
synthetic versatility of quinoline, which allows the generation of a large number of 
structurally diverse structures. 
 The objective of the current study includes: 
 Fragment identification 
 Evaluation of molecules against specific protein target using In-silico 
methods. 
 Synthesis of following compounds 
 (6-chloro-2-phenylquinolin-4-yl)(1H-imidazol-1-
yl)methanone [C1] 
 (6-chloro-2-phenylquinolin-4-yl)(piperidin-1-
yl)methanone[C2] 
 6-nitro-2-phenyl-N-(pyridine-2-yl)-1,2,3,4-
tetrahydroquinoline-4-carboxamide [C3] 
 {2-[4-(dimethyl amino)phenyl]-6-nitro-1,2,3,4-
tetraquinolin-4-yl}(piperidin-1-yl)methanone [C4] 
 {2-[4-(dimethyl amino)phenyl]-6-nitro-1,2,3,4-
tetraquinolin-4-yl}(1H-imidazol-1-yl)methanone [C5] 
 Characterization of the above synthesized compounds by UV Spectroscopy, 
IR Spectroscopy, NMR Spectroscopy and MASS Spectrometry. 
 Cytotoxic studies of the synthesized compounds  using MTT assay technique 
 Toxicological evaluation 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods 
  
4. MATERIALS AND METHODS 
4.1. Homology modeling: 
23
 
Homology model of mTOR kinase domain was built using Accelrys
®
 discovery 
studio.  Modeler algorithm was used to generate the 3D structure of mTOR based on the 
crystal structure of PI3K gamma (PDB ID: 3S2A).   The structure has a resolution of 2.5 Å 
and exists in complex with a quinoline inhibitor. The c-terminal region of human mTOR 
protein sequence was taken from uniprot database (P42345).  The sequence alignment was 
carried out using the ClustalW program to identify homologous regions between the two 
proteins. The catalytic domain of mTOR and PI3K gamma shows maximum of 45% 
similarity.  After the identification of structurally conserved and variable regions, restraints, 
distances and dihedral angles were extracted from the template structure and applied to 
mTOR.  Stereochemical restraints, viz., bond length and bond angle preferences, were 
obtained from the molecular mechanics force field CHARMM.  The quinoline inhibitor 
from the crystal structure was extracted and transferred to mTOR homology model for 
further guidance in docking studies.  mTOR homology model was further refined using 600 
ps MD simulations in explicit water. Minimization was carried out using the consistent 
valence force field (CVFF) with a van der Waals cutoff of 9.5 ˚A and a distance-dependent 
dielectric constant of 1×r. One thousand steps of steepest descents were performed followed 
by 1000 steps of conjugate gradients until the root mean square (RMS) gradient reached a 
value of less than 0.001kcal/mol/Å. The homology models were each solvated with a 10 ˚A 
water layer and optimized using MD simulations for 2 ns at a 300 K temperature.  The 
quality of the model was assessed by PROCHECK.  The model was evaluated by a 
Ramachandran plot and found that 97% of the residues are in favorable region. 
 
 
 
 Fig.4 Homology model of human mTOR in complex with ligand extracted from PI3K 
gamma.  Dotted lines shows the interactions with the protein with Asp 177, Lysine 97 
and Valine 60 
 
 
 
 
 
 
  
 
 Fig.5 Structural overlay of human mTOR with PI3K gamma in complex with ligand.  
Blue – mTOR;  Pink – PI3K gamma 
 
 
 
 
 
 
 
  
4.2.Drug design: 
 24,25
 
 A drug is a small molecule ligand that binds to a specific protein which either 
increases its activity (an agonist) or decrease/block its activity (an antagonist). One way to 
find promising drug candidates is to investigate how the target protein interacts with 
randomly chosen compounds. Drug designing basically of two types namely ligand based 
approach or receptor based approach. 
 Ligand-based drug design (or indirect drug design) relies on knowledge of 
other molecules that bind to the biological target of interest. These other 
molecules may be used to derive a pharmacophore model that defines the 
minimum necessary structural characteristics a molecule must possess in 
order to bind to the target. 
 Structure-based drug design (or direct drug design) relies on knowledge of 
the three dimensional structure of the biological target obtained through 
methods such as x-ray crystallography or NMR spectroscopy.  If an 
experimental structure of a target is not available, it may be possible to create 
a homology model of the target based on the experimental structure of a 
related protein. 
4.2.1. Pharmacophore studies using catalyst: 26, 27, 28 
 Pharmacophore means “a molecular framework that carries (phoros) the essential 
features responsible for a drugs (pharmacon) biological activity”. 
 
  
Catalyst
®
 4.11 from accelrys: 
For Rational design of small molecules as drug candidates using 3D pharmacophore 
and shape-based models, and to suggest potentially active compounds suitable for synthesis 
and biological testing. The typical features are hydrogen bond acceptor (HBA), hydrogen 
bond donor (HBD), hydrophobic (HY), hydrophobic aliphatic, hydrophobic aromatic, 
positive ionizable, negative ionizable and ring aromatic(RA).  
Chemical feature based models from Catalyst
®
 4.11: 
 HipHop 
  Generates a set of common feature pharmacophore models from set of 
compounds known to be active (No activity data) at a specific target. 
 HypoGen 
Develop SAR hypothesis models from a set of molecules for which activity 
values (IC50 or Ki) on a given biological target are known. 
 HypoRefine  
Permits consideration of exclusion volumes in pharmacophore-based 3D 
QSAR optimization. The result is to better model predictivity where biological 
activity is determined by considerations of molecular shape. 
 Exclusion volume 
An excluded volume can be added to a hypothesis (or to a template molecule) 
to specify one or more spherical spaces that must not contain any atoms or 
bonds. An exclusion volume can represent a region in space that might 
impinge sterically on a receptor. An exclusion volume can be interpreted as a 
geometrical constraint, and this is how it is treated in catalyst
®
. 
 
 Compare/Fit 
Provides the ability to fit compounds and hypotheses, and determine their 
degree of similarity, both geometrically and functionally. In database search, 
COMPARE fits the original hypothesis onto the hit molecules obtained from 
the search and score are calculated according to the geometrical fit. 
 Cost parameters 
o Fixed cost represents the simplest possible hypothesis (initial) that fits 
the data perfectly. 
o Null hypothesis-It is the costs when each molecule estimated as mean 
activity. It acts like a hypothesis with no features. 
o Error cost-The bits needed to describe the error in the leads. It 
increases as the RMS difference between estimated and measured 
activities for training set molecules increases. 
o Weight cost-The bits required to describe the feature weights. 
o Configuration cost-The bits required to describe the types and relative 
positions of the features in the hypothesis. A fixed cost that depends 
on the  
-main assumption made by HypoGen is that an active 
molecule 
-should map more features than an inactive molecule 
-complexity of the hypothesis space being optimized 
 
 
 HipHop model (Qualitative): 
 Identifies configurations or three-dimensional spatial arrangements of 
chemical features that are common to molecules in a training set. 
 HipHop matches the chemical features of a molecule against drug 
candidate molecules or searches of 3D databases. 
 The resulting hypotheis can be used to iteratively search chemical databases 
to find new lead candidates. 
HypoGen model(Quantitative): 
 Creates SAR hypothesis models from a set of molecules for which activity 
values are known. 
 Selects pharmacophore that are common among the active compounds but 
not among the inactive compounds, then optimizes the pharmacophores using 
simulated annealing. 
 Best pharmacophores can be used to predict the activity of unknown 
compounds or to search for new possible leads contained in 3D chemical 
databases.  
 Selection of training set is very important, since the hypotheses are derived 
directly from the information in the training set. 
The quality of HypoGen model are best described in terms of cost analysis. 
 
  
4.2.2. Data set: 
  Pharmacophore modeling correlates activities with the spatial arrangement of 
various chemical features in a set of active analogues.  The compounds in this study were 
collected from a series of mTOR inhibitors published in recent years, considering both 
structural diversity and wide coverage of the activities.  A set of 297 human mTOR 
inhibitors with an activity range (IC50) 0.0016-11000 nM was selected.  This initial group 
was then divided into the training set and test set.  The training set of 24 molecules was 
designed to be structurally diverse with a wide activity range.  Molecules with Ki, ED50, 
EC50 and other activity type values were ignored and not considered for modeling studies.  
The training set molecules play a critical role in the pharmacophore generation process and 
the quality of the resultant pharmacophore models relies solely on the training set molecules.  
The test set of remaining 273 molecules is designed to evaluate predictive ability of the 
resultant pharmacophore.  Highly active, moderately active, and inactive compounds were 
added to the training set to obtain critical information on pharmacophoric requirements for 
mTOR inhibition.  The molecules selected as the training set are given in fig.6 and a few 
molecules from test set are given in fig.7.  This training set was then used to generate 
quantitative pharmacophore models.  While generating a quantitative model, a minimum of 
0 to a maximum of 4 features involving hydrophobic acceptor (HBA), hydrophobic donor 
(HBD), hydrophobic aliphatic and ring aromatic (RA) were selected and used to build a 
series of hypotheses using a default uncertainity value of 3.  The quality of HypoGen models 
is best described in catalyst user guide in terms of fixed cost, null cost and total cost and 
other statistical parameters.  According to which, a large difference between the fixed cost 
and null cost, and a value of 40-60 bits for the unit of cost would imply a 75-90% 
probability for experimental and predicted activity correlation.  In general, pharmacophore 
models should be statistically significant, predict the activity of molecules accurately, and 
retrieve active compounds from a database.  The derived pharmacophore models were 
validated using a set of parameters including cost analysis, test set prediction, enrichment 
factors, and goodness of fit.  HipHop and HypoGen modules within catalyst were then used 
to generate qualitative pharmacophore and quantitative pharmacophore models respectively. 
 
4.2.3. Conformational analysis: 
   Molecular flexibility was explored by considering each compound as a collection 
of conformers representing different areas of the conformational space accessible to the 
molecule which in a given energy range.  The conformational space of each compound was 
extensively sampled utilizing the Poling algorithm and CHARMM force field parameters 
with an energy threshold of 20Kcal/mol from the lowest energy level and a maximum of 250 
conformers for compounds predicting their activities accurately and further performing a 
database searching. 
  
 Fig. 6 Training set molecules 
  
Fig. 7 Test set molecules 
 
 
4.2.4. Database searching: 
 Virtual screening of chemical databases can serve the purpose of finding novel, 
potential leads suitable for further development.  Database searching methodology provides 
the advantage that the retrieved compounds can be obtained easily for biological testing 
when compared to any de novo design methods.  A molecule must fit on all the features of 
the pharmacophore model that is used as 3D query in database searching to be retained as 
hit.  Two database searching options such as Fast/Flexible and Best/Flexible search are 
available in DS.  Better results can be achieved using Best/Flexible search option during 
database screening.  
4.2.5. Molecular Docking: 29,30 
 Molecular docking is a computationally intensive SBVS technique that generates 
and scores putative protein-ligand complexes according to their calculated binding affinities.  
Given the crystal structure of the target, molecular docking automatically samples ligand 
conformations and protein ligand interactions with a specified region of the protein surface.  
It has been successfully used for identifying active compounds by filtering out those that do 
not fit into the binding sites.  In absence of the structural information of the target, a 
homology model can be constructed and used for the molecular docking.  In this study, 
molecular docking was performed with a homology model of mTOR by the program Glide
®
. 
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REWARDS:                 
Table 1: 
 
 
Ligand  
G 
Score 
Lipophilic 
Evdw 
PhobEn PhobEn 
HB 
PhobEn 
PairHB 
H 
bond 
Elect Site 
map 
Pi 
Cat 
ClBr Low 
Mw 
1 -8.05 -3.71 -1.22 -1.5 0 -
1.36 
-0.82 -
0.03 
0 0 -0.19 
2 -6.61 -3.97 -1.55 0 0 -0.9 -0.11 -0.4 0 0 -0.38 
3 -6.14 -4.08 -1.7 0 0 -
0.35 
-0.13 -
0.26 
0 0 -0.13 
4 -6.04 -4.67 -1.20 0 0 0 -0.23 -
0.31 
0 0 -0.19 
5 -4.85 -3.75 -1.57 0 0 0 -0.06 -
0.21 
0 0 -0.33 
 
 
 
 
PENALTIES: 
Table 2: 
 
 
 
 
 
 
 
 Ligand Penalties HB Penal PhobicPenal RotPenal 
1 0 0 0.59 0.21 
2 0 0 0.49 0.21 
3 0 0 0.37 0.15 
4 0 0 0.42 0.16 
5 0 0 0.88 0.19 
  
Fig. 8 Ligand binding with the receptor  
 
 
 
4.2.6. Lipinski’s rule: 31 
 Lipinski’s rule is to evaluate druglikeness of a chemical compound. Changes in the 
compound’s bioactivity adjust to Lipinski’s rule of five. The physical properties of the 
molecules were calculated using Molinspiration molecular properties calculator. The result 
values are given in table 3. 
Table 3: 
 
Compound 
No. 
Log 
P 
Mol.Wt HBA HBD Rotatable 
Bonds 
TPSA Mol.vol. No. of 
Violations 
1 3.27 374.4 7 2 4 99.84 329.44 0 
2 4.24 333.77 4 0 2 47.78 280.42 0 
3 3.72 408.50 7 1 4 81.39 381.64 0 
4 3.02 391.43 8 1 4 95.98 348.31 0 
5 4.59 350.84 3 0 2 33.20 313.75 0 
 
 
 
Log P- Partition Coefficient 
Mol.Wt- Molecular Weight 
HBA- Hydrogen Bond Acceptor 
HBD- Hydrogen Bond Donor 
TPSA- Total Polar Surface Area 
Mol. Vol.- Molar Volume 
 
                   
4.3. Synthesis: 
32, 33 
 
Step 1: 
  Pyruvic acid (22ml, 0.25 mol) in 200 ml of ethanol and benzaldehyde (24ml, 0.236 
mol) were mixed and heated up to the boiling point. A solution of pure aniline (23ml, 0.248 
mol) in 100 ml of ethanol was added. The addition was done for 1hr. The mixture was 
refluxed for about 3 hr and allowed to stand overnight. 
 
Step 2: 
 Prepared 2-phenyl-quinoline carboxylic acid (0.01 mole) and 15 ml of thionyl 
chloride were refluxed for 30 min. Unreacted  thionyl chloride was removed by heating the  
reaction mixture on a water bath. 
 
Step 3: 
 The above obtained acid chloride product was treated with 3 to 4 times of different 
amines and ethanol as reaction medium and stirred for 5 hrs. It was then added into cold 
water to get the precipitate, which was filtered and recrystallized from suitable solvent. 
 
 
 
 
 
Scheme I: 
Step 1: 
NH2
R
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CHO
+ CH3
COOH
O
N
COOH
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Step 2: 
 
N
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R
N
COCl
R
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Step 3: 
N
COCl
R
N
CO-R'
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Where R=Cl; R’=Imidazole/Piperidine 
 
 
 
 
SCHEME II: 
Step 1: 
NH2
R
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Step 2: 
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Step 3: 
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Where R=NO2; R’=Imidazole/Piperidine/2-amino pyridine 
 
 
 
 
 
4.3.1. Recrystallization: 
 Ethanol was added to the synthesized compound and heated until it dissolved 
completely. The clear solution thus obtained was filtered immediately and set aside for 
cooling. On cooling crystals gradually appeared. 
4.3.2. Methods for Identification: 
   Melting Point: 
 The melting points of the compounds were determined by capillary tube method. The 
temperature at which the synthesized compounds started losing its crystallinity were found 
and are presented uncorrected. 
  Thin Layer Chromatography: 
 Precoated Aluminium TLC-GF binder was used. Solution of the reactant and 
products in ethanol was prepared. Various mobile phases were tried out of which methanol 
and chloroform were found to be suitable. 
 Stationary Phase: Precoated Silica gel GF plates 
 Mobile phase: Methanol and Chloroform (9:1) as developing solvent system for 
synthesized compounds 
Location of Spots: UV chamber 
A single principle spot and absence of secondary spot and spot for parent compounds 
confirmed the purity of the compounds. 
 
 
 
 
4.3.3. CHARACTERIZATION: 
34, 35, 36
 
 
 The compounds were found to have sharp melting points. The melting points 
are uncorrected. 
 
 The synthesized molecules were subjected to TLC technique and found to be 
pure. Only a single spot was noticed for the synthesized compound. 
 
 
 The synthesized molecules were characterized by IR Spectroscopy using 
ABB Spectrophotometer in the range of 4000 to 400cm
-1
. 
 
 Proton NMR spectra were recorded using solvent deuterated methanol on 
BRUKER advance III 500 NMR spectrometer. Chemical shifts are reported 
in parts per million (ppm). 
 
 
 The MASS spectra were recorded on JEOL GC Mate II Mass 
Spectrophotometer operating as direct probe using Electron Ionization (EI) 
technique. 
 
 
 
Step I: 
 
Step II: 
 Reactants Product (B1-B5) 
A1-A5 Thionyl 
chloride 
Reaction 
process 
Comp. Mol. Formula Mol. 
Wt. 
M.P 
(°C) 
Mole 0.01  
 
 
15ml 
 
 
 
 
Reflux 
30 min 
B1 C16H13Cl2N2O3 316.73 276 
 
 
Amount 
 
 
2.83gm 
 
B2 C16H9Cl2NO 302.15 296 
B3 C18H18ClN3O3 359.80 312 
B4 C18H18ClN3O3 359.80 312 
B5 C16H9Cl2NO 302.15 296 
 
Comp. – Compound, Mol. Formula- Molecular Formula, Mol. Wt.-Molecular weight, M.P- 
Melting Point. 
 
 
 
 Reactants Product (A1-A5) 
Substituted 
Aniline 
Aldehyd
e 
Pyruvic 
acid/ 
Lactic 
acid 
Reaction 
process 
Com
p. 
Mol. Formula Mol. 
Wt. 
M.P 
(°C) 
Mole 0.248 0.236 0.25  
 
 
 
Reflux 3 
hrs 
A1 C16H14N2O4 298.29 282 
 
 
Volum
e 
 
 
 
23ml 
 
 
24ml 
 
 
22ml 
A2 C16H10ClNO2 283.70 324 
A3 C18H19N3O4 341.36 276 
A4 C18H19N3O4 341.36 276 
A5 C16H10ClNO2 283.70 324 
Step III: 
 
 
 Reactants Product (C1-C5) 
B1-B5 Different 
Amines 
Reaction 
medium 
Reaction 
process 
Comp. Mol. 
Formula 
Mol. 
Wt. 
M.P 
(°C) 
Mole  0.01 0.03  
 
 
 
Ethanol 
(25ml) 
 
 
 
 
Reflux 5 
hrs 
C1 C21H18N4O3 374.39 76 
 
 
Weight 
 
3.02gm 
 
1)2.82gm 
 
2)2.04gm 
 
3)2.55gm 
 
4)2.04gm 
 
5)2.55gm 
 
 
C2 C19H12ClN3O 333.77 90 
C3 C23H28N4O3 408.49 212 
C4 C21H21N5O3 391.42 214 
C5 C21H19ClN2O 350.84 132 
 
Comp. – Compound 
Mol. Formula- Molecular Formula 
 Mol. Wt.-Molecular weight 
M.P- Melting Point 
 
 
 
 
 
 
 
 
 
 
 
4.4.PHARMACOLOGICAL EVALUATION: 
4.4.1. Acute toxicity: 37 
 Acute toxicity is the toxicity produced by the compounds when it is administered in 
one or more doses during a period not exceeding 24 hours. 
Acute toxicity studies in animals are usually necessary for any compounds intended 
for human use. The information obtained from these studies is useful in choosing doses for 
repeat-dose studies, providing preliminary identification of target organs of toxicity, and, 
occasionally, revealing delayed toxicity. Acute toxicity studies may also aid in the selection 
of starting doses for Phase I human studies, and provide information relevant to acute 
overdosing in humans. 
This acute toxicity study was designed as per the OECD Guidelines for Testing of 
Chemicals, Acute Oral Toxicity (Acute Toxic Class Method), Guideline 423. 
Principle of the test: 
Acute toxicity testing determines the toxicity of a chemical or drug substances after 
single administration. 
   Today, acute toxicity testing focuses on levels on acute tolerance, nature of acute 
toxicity symptoms in the sub-lethal range, and dose levels which cause mortality in two 
animals i.e. quality has replaced quantity. 
   It is the principle of the test that based on a stepwise procedure with the use of a 
minimum number of animals per step. The substance was administered orally to a group of 
experimental animals at one of the defined doses. The substance was tested using a stepwise 
procedure, each step using five animals of a single sex (normally females).  Absence or 
presence of compound-related mortality of the animals dosed at one step will determine the 
next step, i.e. 
 no further testing is needed. 
 dosing of three additional animals, with the same dose. 
 dosing of three additional animals at the next higher or the next lower dose level. 
 
Description of the method: 
Experimental animals: 
Healthy adult female Albino mice (5 nos.) were used in research. Females were weighing 
between 20-25mg, for all the four animals food, but not water withheld overnight prior to 
dosing. 
Housing and lighting conditions: 
The temperature in the experimental animal room should be 22ºC (±3ºC). Although the 
relative humidity should be at least 30% and preferably not exceed 70% other than during 
room cleaning the aim should be 50-60%. Lighting should be artificial, the sequence being 
12 hours light, 12 hours dark. For feeding, conventional laboratory diets may be used with 
an unlimited supply of drinking water. Animals may be group-caged by dose, but  
the number of animals per cage must not interfere with clear observations of each animal. 
 
 
 
 
 
 PROCEDURE: 
Administration of doses: 
   The test substance is administered in a single dose by 19 gauge using an oral tube.  
 
Testing procedures: 
     The test compounds should be administered to animal to identify doses causing no 
adverse effects and doses causing major (life-threatening) toxicity. The use of vehicle 
control groups should be considered. For compounds with low toxicity, maximum feasible 
dose should be administered. 
Studies should be conducted in at least two mammalian species, including a non-
rodent species when reasonable. The objectives of acute studies can usually be achieved in 
rodents using small groups of animals (for instance, three to five rodents per sex per dose). 
Where non-rodent species are appropriate for investigation, use of fewer animals may be 
considered. Any data providing information on acute effects in non-rodent species, including 
preliminary dose-range finding data for repeat-dose toxicity studies, may be acceptable. 
 
OBSERVATION: 
The animals were observed individually after dosing once during the first 30 minutes, 
periodically for the first 24 hours, with special attention given during the first 4 hours & 
daily there-after, for a total of 14 days. The following clinical observation were made and 
recorded. 
 Toxic Signs: 
All mice were observed for any toxic signs. 
All the rats were observed for any pre-terminal deaths. 
 Body Weight: 
          Individual body weights were recorded for all the animals once in a week. 
 Cage Side Observation: 
The faeces colour, faeces consistency, changes in skin & fur, eyes & mucous 
membrane (nasal) of the animal were observed once in a week. 
 Physical examination: 
Physical examination included changes in 
 Salivation, lacrymation, perspiration, piloerection, micturition and defecation. 
 Central nervous system: 
Ptosis, drowsiness, gait, eye prominence, eyelid closure, convulsions, biting, 
straub’s test, motor incoordination, writhing, stereotypy, aggression, righting 
reflex, pinna reflex, corneal reflex, tremors and convulsions. 
 
  
 4.4.2. IN VITRO ANTI CANCER ACTIVITY: 38, 39 
The human colorectal carcinoma cell line (HCT116) was obtained from National 
Centre for Cell Science (NCCS), Pune, and grown in Dulbeccos Modified Eagles Medium 
(DMEM) containing 10% fetal bovine serum (FBS). All cells were maintained at 37
0
C, 5% 
CO2, 95% air and 100% relative humidity. Maintenance cultures were passaged weekly, and 
the culture medium was changed twice a week. 
Cell treatment procedure 
 The monolayer cells were detached with trypsin-ethylenediaminetetraacetic acid 
(EDTA) to make single cell suspensions and viable cells were counted using a 
hemocytometer and diluted with medium with 5% FBS to give final density of 1x10
5
 
cells/ml. one hundred microlitres per well of cell suspension were seeded into 96-well plates 
at plating density of 10,000 cells/well and incubated to allow for cell attachment at 37
0
C, 5% 
CO2, 95% air and 100% relative humidity. After 24 h the cells were treated with serial 
concentrations of the extracts and fractions. They were initially dissolved in neat 
dimethylsulfoxide (DMSO) and further diluted in serum free medium to produce five 
concentrations. One hundred microlitres per well of each concentration was added to plates 
to obtain final concentrations of 100, 10, 1.0 and 0.1 µM. The final volume in each well was 
200 µl and the plates were incubated at 37
0
C, 5% CO2, 95% air and 100% relative humidity 
for 48h. The medium containing without samples were served as control. Triplicate was 
maintained for all concentrations. 
MTT assay:  
40, 41
  
 MTT is a yellow water soluble tetrazolium salt. A mitochondrial enzyme in living 
cells, succinate-dehydrogenase, cleaves the tetrazolium ring, converting the MTT to an 
insoluble purple formazan. Therefore, the amount of formazan produced is directly 
proportional to the number of viable cells. 
 After 48h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) 
was added to each well and incubated at 37
0
C for 4h. The medium with MTT was then 
flicked off and the formed formazan crystals were solubilized in 100µl of DMSO and then 
measured the absorbance at 570 nm using micro plate reader. The % cell inhibition was 
determined using the following formula.  
% cell Inhibition = 100- Abs (sample)/Abs (control) x100.  
Nonlinear regression graph was plotted between % Cell inhibition and Log10 
concentration and IC50 was determined using GraphPad Prism software. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
5. RESULTS AND DISCUSSION  
Our efforts to synthesize novel anticancer compounds based on drug 
design lead to the following results and discussed accordingly. 
5.1.Pharmacophore model and validation: 
 The main purpose of validating a quantitative pharmacophore model is to determine 
whether it is capable of identifying active compounds predicting their activities accurately 
and further performing database searching.  Two validation procedures were followed 
namely, Test set prediction method and Cat-scramble method.  The Cat-scramble validation 
procedure is a cross-validation based on Fischer’s randomization test.  The goal of this type 
of validation is to check whether there is a strong correlation between the chemical 
structures and the biological activity.  This is done by randomizing the activity data 
associated with the training set compounds, generating pharmacophore hypotheses using the 
same features and parameters to develop the original pharmacophore model. 
17 run Active:                                                       15 run Active: 
 
  
17 run Inactive:                                                    15 run Inactive: 
 Pharmacophore:                                      Pharmacophore distance: 
 
Fig. 9 Pharmacophore modeling 
Table 4: 
Statistical parameters from screening of test set molecules: 
S.No. Parameter mTOR 
1 Total compounds in database (D) 297 
2 Total Number of actives in database (A) 170 
3 Total Hits (Ht) 176 
4 Active Hits (Ha) 162 
5 % Yield of Actives [(Ha/ Ht)*100] 92.05 
6 % Ratio of actives in the Hit list [(Ha/A)*100] 95.29 
7 Enrichment factor or Enhancement (E)  [(Ha * 
D)/(Ht*A)] 
1.61 
8 False Negatives [A-Ha] 8 
9 False Positives [Ht- Ha] 14 
10 GH score (Goodness of Hit list) 0.83 
[(Ha/4HtA) (3A+ Ht))* (1-(( Ht- Ha)/(D-A))]; GH score of 0.7-0.8 indicates a very good 
model. 
The best common feature pharmacophore model hypo 1 (from outhypo 17) and hypo 
3 (from outhypo 15) indicated the importance of H-bond acceptor (HBA), H-bond donor 
(HBD), Hydrophobic (HY), and ring aromatic (RA) features, which were further confirmed 
in the quantitative models.  3D QSAR pharmacophore Generation module/Discovery studio 
(DS) was used to construct pharmacophore model using the above mentioned features.  It 
produced ten top-scored hypotheses based on the activity values of the training set 
molecules.  The best ten hypotheses contain only HBA, HBD, RA and Hydrophobic 
features. Hypo 1 consist of 2 HBA, 3 HY and Hypo 3 consist of HBA, HBD, RA which 
establishes the highest cost difference, lower errors, best correlation coefficient, maximum 
fit value, and lowest root mean square deviation (RMSD) (table 5 & 6).  The fixed and the 
null costs values are 99.7202(for outhypo 17), 98.8074(for outhypo 15) and 140.601 
respectively.  Fixed total cost was dependent on summation of the cost components: weight 
cost, error cost, and configuration cost.  Two key values were used for cost analysis: one is 
the difference between the fixed and null costs and another one is the difference between 
null and total costs (cost difference).  The fixed cost represents a cost of the theoretical ideal 
hypothesis, which could absolutely predict the activity of compounds in the training set with 
lowest deviation, while null cost represented the cost of hypothesis with no features that 
estimates every activity to be the average activity.  The difference between these two costs 
should be ≥70 bits to show the over 90% statistical significance of the model.  The cost 
difference should be greater than 60 bits to represent a true correlation data. 
 
 
 
 
 
 
Pharmacophore Models generated by HypoGen: 
Table 5: 
Outhypo 17: 
Hypo.No. Total 
cost 
Fixed 
cost 
Cost 
difference 
RMSD Correlation Features Max. fit 
1 117.729 99.7202 22.872 1.2249 0.836 HBA,HBA,HY,HY,HY 10.1229 
2 117.824 99.7202 22.777 1.2217 0.837 HBA,HBA,HY,HY,HY 10.9338 
3 117.875 99.7202 22.726 1.2296 0.834 HBA,HBA,HY,HY,HY 9.7913 
4 118.19 99.7202 22.411 1.2383 0.832 HBA,HBA,HY,HY,HY 9.443 
5 118.755 99.7202 21.846 1.2593 0.825 HBA,HBD,HBD,HY 8.0423 
6 118.76 99.7202 21.841 1.2387 0.833 HBA,HBA,HY,HY,HY 11.6888 
7 118.946 99.7202 21.655 1.2654 0.824 HBA,HBD,HBD,HY 8.1714 
8 120.155 99.7202 20.446 1.3005 0.813 HBA,HBA,HBA,HY 8.6328 
9 120.875 99.7202 19.726 1.3216 0.806 HBA,HBD,HBD,HY 8.7544 
10 120.949 99.7202 19.652 1.3281 0.804 HBA,HBA,HY,HY,HY 9.4722 
 
Null Hypothesis: 
     Total cost – 140.601; RMS – 2.23373; Error – 140.601 
 
 
 
 
 
 
 
 
 
 
 
Pharmacophore Models generated by HypoGen: 
 
Table 6: 
 
Outhypo 15: 
Hypo.No. Total 
cost 
Fixed 
cost 
Cost 
difference 
RMSD Correlation Features Max. fit 
1 123.316 98.8074 17.285 1.4290 0.7685 HBA,HBD,HBD,HYALI 7.9201 
2 123.765 98.8074 16.836 1.3811 0.7932 HBD,HYALI,RA,RA 10.4565 
3 123.767 98.8074 16.834 1.3173 0.8263 HBA,HBD,RA 8.6055 
4 124.173 98.8074 16.428 1.4517 0.7601 HBA,HBD,HBD,HYALI 8.4634 
5 124.504 98.8074 16.097 1.4289 0.7723 HBD,HBD,HYALI,RA 9.8660 
6 124.735 98.8074 15.866 1.4691 0.7533 HBA,HBA,HBD,HYALI 8.2707 
7 124.811 98.8074 15.79 1.4425 0.7666 HBD,HBD,HYALI,RA 9.7348 
8 124.845 98.8074 15.756 1.4266 0.7750 HBD,HYALI,RA,RA 10.1712 
9 124.846 98.8074 15.755 1.4065 0.7856 HBD,HYALI,RA,RA 10.5895 
10 125.056 98.8074 15.545 1.4697 0.7532 HBD,HBD,HYALI,RA 8.9747 
Null Hypothesis: 
     Total cost – 140.601; RMS – 2.2337; Error – 140.601 
 
 
 
 
 
 
 
 
 
Experimental and Predicted IC50 data of 24 training set molecules: 
Table 7: 
Outhypo 15(Hypo 3) 
Compound 
No. 
IC50 ERROR FIT 
VALUE 
ACTIVITY SCALE MAPPED 
FEATURES EXPERIMENTAL PREDICTED 
Experimental predicted HBA HBD RA 
1 0.0016 0.047 29 7.99 +++ +++ 18 30 16 
2 0.29 4.2 15 6.04 +++ ++ 11 17 16 
3 0.35 0.55 1.6 6.92 +++ +++ 19 14 16 
4 0.42 0.34 -1.2 7.13 +++ +++ 20 11 10 
5 0.46 3.1 6.7 6.17 +++ ++ 21 23 16 
6 0.63 3.3 5.3 6.14 +++ ++ 17 13 12 
7 0.75 3.3 4.4 6.15 +++ ++ 20 15 13 
8 0.9 1.1 1.2 6.62 +++ ++ 13 17 16 
9 1.2 0.17 -7.1 7.43 ++ +++ -17 -20 -18 
10 1.6 10 6.5 5.64 ++ ++ -19 -13 -12 
11 2.6 1.5 -1.7 6.48 ++ ++ 19 15 13 
12 2.9 1.4 -2.1 6.52 ++ ++ 17 14 12 
13 3.9 2.9 -1.3 6.19 ++ ++ -14 -11 -1 
14 5.6 1.6 -3.5 6.46 ++ ++ 16 27 7 
15 7 3.2 -2.2 6.15 ++ ++ -35 -31 -6 
16 9.6 14 1.4 5.53 ++ + 17 19 * 
17 13 15 1.1 5.49 + + -12 -17 -1 
18 18 14 -1.3 5.53 + + -15 -17 -1 
19 26 18 -1.4 5.40 + + * -16 -1 
20 34 8.6 -3.9 5.73 + ++ -17 -14 -1 
21 51 15 -3.4 5.48 + + 12 20 15 
22 71 11 -6.2 5.60 + + -24 -17 -6 
23 94 24 -3.8 5.27 + + * 10 13 
24 140 22 -6.7 5.32 + + 16 20 * 
 
 
 
 
 
 
 
 
 
Experimental and Predicted IC50 data of 24 training set molecules: 
Table 8: 
Outhypo 17 (Hypo 1) 
 
COM
POU
ND 
NO. 
IC50  
ERROR 
 
FIT 
VALUE 
 
ACTIVITY SCALE 
 
MAPPED FEATURES  
EXPERI
MENTAL 
 
PREDI
CTED 
Experime
ntal 
Predicted 
HBA HBA HY HY HY 
1 0.0016 0.0033 2.1 9.85 +++ +++ 30 19 21 29 25 
2 0.29 2.7 9.1 6.94 +++ ++ -9 -6 -23 * -33 
3 0.35 1.1 3.1 7.34 +++ ++ -4 -8 -30 * -28 
4 0.42 2.7 6.5 6.93 +++ ++ 2 4 26 * 23 
5 0.46 1.8 3.8 7.12 +++ ++ 11 3 14 36 * 
6 0.63 0.98 1.6 7.38 +++ +++ -7 -6 -23 * -20 
7 0.75 1 1.4 7.35 +++ ++ 7 6 22 * 25 
8 0.9 1.2 1.3 7.30 +++ ++ -8 -4 -23 * -35 
9 1.2 1.7 1.4 7.13 ++ ++ 9 4 33 * 37 
10 1.6 1.1 -1.4 7.32 ++ ++ -4 -8 -27 * -29 
11 2.6 0.91 -2.8 7.41 ++ +++ 7 6 30 * 29 
12 2.9 2.7 -1.1 6.93 ++ ++ 7 6 23 * 32 
13 3.9 3.9 -1 6.78 ++ ++ -3 -4 20 * -34 
14 5.6 4.5 -1.3 6.72 ++ ++ 16 12 11 31 * 
15 7 3.1 -2.2 6.87 ++ ++ 13 35 28 37 * 
16 9.6 57 6 5.61 ++ + 6 7 28 * * 
17 13 0.75 -17 7.50 + +++ 9 4 22 * 34 
18 18 58 3.2 5.60 + + -6 -5 -28 * * 
19 26 41 1.5 5.75 + + 19 * 8 13 26 
20 34 36 1 5.82 + + * -16 -18 * -34 
21 51 33 -1.6 5.85 + + * 19 22 * 34 
22 71 22 -3.3 6.03 + + * * 25 14 27 
23 94 3.1 -30 6.88 + ++ -2 -5 -24 * -11 
24 140 26 -5.5 5.95 + + * * 4 28 31 
 
5.2.Docking studies: 
   Molecular docking was executed for accurate docking of ligand into protein active 
sites.  Docking experiments were performed using Glide
®
.  For docking study, initially 
protein was prepared by removing all water molecules.  After the protein preparation, the 
active sites in the protein have to be identified.  The active site of the protein was 
represented as binding site; it’s a set of points on a grid that lie in a cavity.  The binding site 
for the protein is defined by the volume occupied by the known ligand pose already in an 
active site.  During docking process, Glide initially performs a complex systematic search of 
conformation, orientation and position of a compound in a defined binding site and 
eliminated unwanted poses using scoring and energy optimization.  Finally the 
conformations were refined via a Monte Carlo Sampling.  Docking poses were energy 
minimized using OPLS-2001 force field.  The best pose was selected based on Glide score 
and the favorable interactions formed between the compound and amino acid residues of the 
mTOR active site.  All the ligands in the complex structures showed the hydrogen bond 
interactions with Asp 64, Asp 177, Lys 7, Val 60, Gly 64, and Asp 15 (fig.10).  This clearly 
indicates that these hydrogen bonded amino acids play a crucial role in mTOR inhibition 
activity.  During the docking process top 10 conformations was generated for each ligand 
based on dock score value after the energy minimization process. 
 
 
Fig. 10 Interactions 
 
 
 
 
 
 
 
 
 
 
5.3.Synthesis and characterization: 
Table 9: 
Synthesis and identification of Quinoline and Tetrahydroquinoline derivatives: 
Compo
und no. 
C-1 C-2 C-3 C-4 C-5 
 
Product 
N
H
NHO
O2N
N
 
N
Cl
N
N
O
 
N
H
NO
O2N
NMe2 
N
H
NO
O2N
NMe2
N
 
N
NO
Cl
 
 
Recryst
allizatio
n 
 
Ethanol 
 
Ethanol 
 
Ethanol 
 
 
Ethanol 
 
Ethanol 
 
Yield 
(%) 
 
76 
 
78 
 
75 
 
80 
 
77 
 
Melting 
Point 
 
76
0
C 
 
90
0
C 
 
212
0
C 
 
214
0
C 
 
132
0
C 
 
TLC 
 
Precoated 
silica gel 
GF plates 
 
Precoated 
silica gel 
GF plates 
 
Precoated 
silica gel 
GF plates 
 
Precoated 
silica gel 
GF plates 
 
Precoated 
silica gel 
GF plates 
 
 
Station
ary 
Phase 
Mobile 
Phase 
 
Methanol/
Chlorofor
m 
 
Methanol/
Chlorofor
m 
 
Methanol/
Chlorofor
m 
 
Methanol/
Chlorofor
m 
 
Methanol/
Chlorofor
m 
 
Locatio
n of 
spots 
 
UV 
Chamber 
 
UV 
Chamber 
 
UV 
Chamber 
 
UV 
Chamber 
 
UV 
Chamber 
IR 
spectro
scopy  
(cm
-1
) 
 
1304(C-
N) 
1474(Ar 
C=C) 
1597(C-
NO2) 
1636(C=O
) 
2962(Ar 
C-H) 
3479(N-
H) 
 
 
756(C-Cl) 
1311(Ar 
C-N) 
1628(Ar 
C=C) 
1674(C=O 
of Amide) 
2932(Ar 
C-H) 
 
1319(C-
N) 
1373 cm
-1
 
(N(CH3)2) 
1458(Ar 
C=C) 
1551(C-
NO2) 
1651(C=O
) 
3070(Ar 
C-H) 
 
 
 
1319(C-
N) 
1373 cm
-1
 
(N(CH3)2) 
1458(Ar 
C=C) 
1551(C-
NO2) 
1643(C=O
) 
3063(Ar 
C-H) 
 
764(C-Cl) 
1311(Ar 
C-N) 
1497(Ar 
C=C) 
1674(C=O 
of Amide) 
2978(Ar 
C-H) 
 
 
NMR 
spectro
scopy 
1.6 (4 H) 
6.1(4H,Ar
) 
6.6(4H,Ar
) 
7.2(1,NH) 
8.1(4H, 
Het.Ar) 
9.9(1H,N
H) 
6.6(3H,Ar
) 
7.5(5H,Ar
) 
7.9(3H, 
Het.Ar) 
8.4(1H, 
Het.Ar) 
2.4(6H, 
N(CH3)) 
2.9(4H) 
3.2(10H) 
7.0(1H,N
H) 
7.6-9.6 
(7H,Ar) 
2.4(4H) 
3.3(6H, 
N(CH3)) 
6.2-6.9 
(7H,Ar) 
7.6-
7.9(3H, 
Het.Ar) 
9.7(1H,N
H) 
1.6(10H) 
6.1,6.4,6.6 
(8H,Ar) 
7.9(1H, 
Het.Ar) 
MASS 
spectro
metry 
374.41(M
+
, 6%) 
140.30 
(B,100%) 
 
333.38(M
+
,12%) 
61.77 
(B,100%) 
408.52(M
+
,6%) 
61.77 
(B,100%) 
391.42(M
+
,7%) 
135.21 
(B,100%) 
350.88(M
+
,10%) 
62.57 
(B,100%) 
  
  
IR spectrum of compound 1: 
 
 
 
 
 
Fig. 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NMR spectrum of compound 1: 
 
 
Fig. 12 
 
 
 
 MASS spectrum of compound 1: 
 
 
 
Fig. 13 
 
 
 
IR spectrum of compound 2: 
 
 
 
 
 
Fig. 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NMR spectrum of compound 2: 
 
 
Fig. 15 
 
 
 MASS spectrum of compound 2: 
 
 
 
 
Fig. 16 
 
 
 
 
IR spectrum of compound 3: 
 
 
 
 
 
 
 
Fig. 17 
 
 
 
 
 
 
 
 
 
 
 
NMR spectrum of compound 3: 
 
 
 
Fig. 18 
 
 
 
 
 
MASS spectrum of compound 3: 
 
 
 
Fig. 19 
 
 
 
 
IR spectrum of compound 4: 
 
 
 
 
 
 
Fig. 20 
 
 
 
 
 
 
 
 
 
 
 
 
NMR spectra of compound 4: 
 
Fig.  21 
 
 
 
 
 MASS spectrum of compound 4: 
 
 
Fig.22 
 
 
 IR spectrum of compound 5: 
 
 
 
 
 
Fig.23 
 
 
 
 
 
 
 
 
 
 
 NMR spectrum of compound 5: 
 
 
Fig.24 
 
 
 MASS spectrum of compound 5: 
 
  Fig. 25 
5.4.Pharmacological evaluation: 
Table 10:  
5.4.1. Acute toxicity studies: 
Behavioural and physical observations of mice following the administration of synthesized 
compounds for the dose limit of 300mg/kg body weight. 
 
S.No PARAMETER 0 min 1 hr 4hrs 8hrs 1 week 2 weeks 
1 Straub’s test  -     
2 Sedation  - - - - - 
3 Excitation - - - - - - 
4 Jumping - - - - - - 
5 Writhing - - - - - - 
6 Piloerection - - - - - - 
7 Stereotypy - - - - - - 
8 Scratching - - - - - - 
9 Grooming - - - - - - 
10. Aggression - - - - - - 
11 Ptosis - - - - - - 
12 Exophthalmia - - - - - - 
13 Loss of 
righting reflex 
- - - - - - 
14 Loss of pineal 
reflex 
- - - - - - 
15 Loss of corneal 
reflex 
- - - - - - 
16 Salivation Normal Normal Normal Normal Normal Normal 
17 Lacrimation - - - - - - 
18 Skin and fur Normal Normal Normal Normal Normal Normal 
19 Eyes Normal Normal Normal Normal Normal Normal 
20 Tremors       
21 Diarrhoea       
22 Coma    - - - 
5.4.2. Cytotoxicity studies: 
Compound 1: 
 
 
 
 
 
Fig.26 
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Fig. 27 
 
 
 
 
 
 
 
 
C1 
Conc. 
µM/ml 
 
 
Absorbance 
 
% 
inhibition 
IC50 
µM/ml 
 
 
R
2
 
0.1 0.564333 1.684088  
97.38 
 
0.9911 
1 0.526 8.362369 
10 0.473333 17.53775 
100 0.281 51.0453 
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C2 
Conc. 
µM/ml 
 
 
Absorbance 
 
% 
inhibition 
IC50 
µM/ml 
 
 
R
2
 
0.1 0.571333 0.464576  
113.2 
 
0.9979 1 0.553667 3.542393 
10 0.51 11.14983 
100 0.301 47.56098 
The cytotoxicity study was carried out for the synthesized compounds. All the 
compounds were screened for its cytotoxicity against human colorectal carcinoma cell line 
(HCT116) at different concentrations to determine the IC50 (50% growth inhibition) by MTT 
assay. 
 Results are tabulated in table 11& 12 and graphically represented in fig. 28&29.  
 The IC50 values of compound 1 and 2 were found to be 97.38 and 113.2 µM/ml and 
R
2
 values were 0.9911 and 0.9979. These two compounds showed more significant effect on 
human colorectal carcinoma cell line (HCT 116) when compared to other compounds. 
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Summary and Conclusion 
  
6. SUMMARY AND CONCLUSION 
 Candidate molecules were docked for anticancer activity against the modeled protein 
target mTOR using drug design software (Maestro 9.1). 
 Twenty five scaffolds were screened with high docking score against mTOR 
inhibitor. These compounds also passed Lipinski’s rule. 
 The scaffold containing quinoline nucleus was selected on the basis of synthetic 
feasibility. 
 All the synthesized compounds were characterized by UV spectroscopy, IR 
spectroscopy, NMR spectroscopy and MASS spectrometry and reported as pure. 
 All the synthesized compounds were subjected to acute toxicity studies to fix the 
LD50. The LD50 value of the title compounds (C1-C5) was expected to be in category 
4 i.e.  
 > 300-2000mg/kg body weight. 
 All the synthesized compounds were subjected to invitro experiment to determine 
anticancer activity using MTT assay procedure against mTOR inhibitor and found to 
be effective. 
 Future studies: 
 Organ toxicity studies 
 Invivo anticancer studies 
The above studies have to be done to reveal that the synthesized compounds (C1, C2, 
C3, C4 and C5) have low side effect profile.  
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